SCHEMBL263771

SCHEMBL263771

CC(C)(c1ccc2cc(C(=O)NCc3ccnc4ccc(F)cc34)ccc2n1)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.40
DDR1 Q08345 5/20 0.39
TRPV1 Q8NER1 2/20 0.39
IDO1 P14902 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CDK8 P49336 1/20 0.37
CLK2 P49760 1/20 0.37
ACVR1 Q04771 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
HTT P42858 2/20 0.37
MMP13 P45452 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP3A4 P08684 1/20 0.36
KLKB1 P03952 1/20 0.36
RORC P51449 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264812 0.91 TRPV1 (0.39) EGLN1DDR1TRPV1CDK8ACVR1
SCHEMBL263858 0.91 SMN1; SMN2 (0.43) EGLN1DDR1TRPV1ADORA2AADORA1
SCHEMBL263302 0.88 EGLN1 (0.39) EGLN1DDR1ADORA2AADORA1HTT
SCHEMBL264386 0.83 SMN1; SMN2 (0.39) EGLN1DDR1ADORA2AADORA1HTT
SCHEMBL265347 0.79 NAMPT (0.43) TRPV1
SCHEMBL263695 0.77 SMN1; SMN2 (0.57) RAB9AHTTMAPK1LMNASMN1; SMN2
SCHEMBL1840774 0.76 ROCK2 (0.45) NPC1RAB9AHTTMAPK1KLKB1
SCHEMBL2008896 0.75 TP53 (0.38) DDR1RORCLMNAEPHX2
SCHEMBL1840633 0.74 HPGD (0.41) HTTKLKB1RORCLMNASMN1; SMN2
SCHEMBL262685 0.72 PPARG (0.46) TRPV1NPC1RAB9AMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 EGLN1 1278/4885DDR1 1006/4885TRPV1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.